April 19, 2017 Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection from Pertussis in Neonatal Animal Study
February 21, 2017 Synthetic Biologics to Report 2016 Year End Operational Highlights and Financial Results on March 2, 2017
January 18, 2017 Synthetic Biologics Confirms Key Features of Pivotal Phase 2b/3 Trial of SYN-010 Pursuant to Consultations with FDA
January 5, 2017 Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI)
December 13, 2016 Synthetic Biologics Announces Granting of U.S. Composition of Matter Patent for SYN-005, Designed for the Treatment and Prevention of Pertussis (Whooping Cough)
